Viatris INC 8-K filings

Viatris Inc. announced second-quarter 2026 financial results, reporting total revenues of $3.8 billion with 5% reported growth and a U.S. GAAP net loss of $119 million, while raising full-year financial guidance.

Viatris Inc. has entered into an amended and restated term loan credit agreement for a $40 billion senior unsecured term loan facility.

Viatris Inc. announced the completion of a public offering of $650 million in 4.250% Senior Notes due 2033.

Viatris Inc. has entered into an underwriting agreement to issue and sell $650,000,000 in aggregate principal amount of 4.250% Senior Notes due 2033.

Viatris Inc. shareholders successfully elected thirteen directors, approved executive compensation, and ratified the appointment of Deloitte & Touche LLP.

Viatris Inc. announced first-quarter 2026 financial results, reporting total revenues of $3.5 billion, an 8% reported increase, and U.S. GAAP net earnings of $176 million.

Viatris Inc. announced that Chief Financial Officer Theodora Mistras will depart, with Chief Accounting Officer Paul Campbell appointed as interim CFO.

Viatris Inc. announced robust financial results for Q4 and full-year 2025, exceeding guidance, completing a strategic review with planned workforce reductions, and providing 2026 financial outlook.

Viatris Inc. announced a change in its Chief Legal Officer role, with Brian Roman departing and Matthew Maletta joining.

Viatris Inc. announced an agreement to sell its equity stake in Biocon Biologics Limited for $815 million, accelerating its return to the global biosimilars market.

Viatris Inc. announced the results of its 2025 annual meeting, where shareholders elected all director nominees, approved executive compensation, and ratified Deloitte & Touche LLP as auditors.

Viatris Inc. announced the appointment of David Simmons to its Compensation Committee and Science and Technology Committee, effective after the 2025 annual meeting of shareholders.

Viatris Inc. reported strong third-quarter 2025 financial results, raising and narrowing its full-year financial guidance ranges for total revenues, adjusted EBITDA, and adjusted EPS, while making progress on its late-stage pipeline and strategic review.

Viatris Inc. has amended its bylaws to refine proxy access nomination procedures and announced May 15, 2026, as the date for its 2026 annual shareholder meeting.

Viatris Inc. reported second quarter 2025 financial results with total revenues exceeding expectations and reiterated its full-year 2025 financial guidance.

Viatris Inc. announced the appointment of David Simmons, a seasoned pharmaceutical industry executive, as an independent member of its Board of Directors, effective immediately.

Viatris Inc. reported its first quarter 2025 financial results, reaffirming its 2025 outlook while facing challenges including a significant goodwill impairment charge.

Viatris Inc. has appointed Frank D'Amelio and Michael Severino to its Board of Directors while announcing the upcoming retirements of Rajiv Malik and Harry Korman.

Viatris announces its fourth quarter and full year 2024 financial results, meeting guidance for total revenues, adjusted EBITDA, and adjusted EPS, while exceeding free cash flow guidance, and provides its 2025 financial outlook, which includes the impact of the Indore facility warning letter and import alert.

Viatris Inc. held its 2024 annual meeting where shareholders approved a stock incentive plan amendment, elected directors, and ratified the selection of their accounting firm, while a non-binding vote on executive compensation failed to pass.

Viatris announced solid third-quarter 2024 financial results, demonstrating growth in its base business and progress in debt reduction and portfolio expansion.

Viatris has entered into a second amended and restated revolving credit agreement, increasing its borrowing capacity to $3.5 billion.

Viatris and its subsidiaries have commenced cash tender offers to purchase outstanding senior notes due in 2025 and 2026, with a focus on debt management.

Viatris announced strong second-quarter 2024 financial results, including total revenues of $3.8 billion and a 2% operational revenue growth on a divestiture-adjusted basis, and raised its full-year new product revenue outlook.

Viatris has finalized the sale of its over-the-counter product business to Cooper Consumer Health for a total consideration of up to $1.95 billion.

Viatris Inc. has appointed Dr. Rogerio Vivaldi Coelho to its Board of Directors as part of its ongoing board refreshment efforts.

Viatris announced strong first quarter 2024 financial results, including operational revenue growth and reaffirmed its 2024 financial guidance.

Viatris exceeded 2023 financial guidance, reporting $15.4 billion in total revenue and announcing a $2 billion share repurchase program, while also providing 2024 financial guidance.

Viatris has finalized an agreement to sell its over-the-counter products business to Cooper Consumer Health after exercising a previously granted option.